Interleukin-9 aggravates doxorubicin-induced cardiotoxicity by promoting inflammation and apoptosis in mice.

[1]  Jie Jiang,et al.  Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway , 2019, Phytotherapy research : PTR.

[2]  A. Ihsan,et al.  Chitosan oligosaccharides prevent doxorubicin-induced oxidative stress and cardiac apoptosis through activating p38 and JNK MAPK mediated Nrf2/ARE pathway. , 2019, Chemico-biological interactions.

[3]  D. Mitra,et al.  An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis , 2019, International journal of molecular sciences.

[4]  Zou Sc,et al.  IL-9 exacerbates the development of chronic obstructive pulmonary disease through oxidative stress. , 2018 .

[5]  N. Yusuf,et al.  Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. , 2018, American journal of physiology. Heart and circulatory physiology.

[6]  F. Zhu,et al.  IL-9 Promotes the Development of Deep Venous Thrombosis by Facilitating Platelet Function , 2018, Thrombosis and Haemostasis.

[7]  Ji-fan Hu,et al.  Cytokine IL9 Triggers the Pathogenesis of Inflammatory Bowel Disease Through the miR21-CLDN8 Pathway. , 2018, Inflammatory bowel diseases.

[8]  Jing Ye,et al.  Circulating Th1, Th2, Th9, Th17, Th22, and Treg Levels in Aortic Dissection Patients , 2018, Mediators of inflammation.

[9]  Jianfang Liu,et al.  Interleukin-12p35 Knock Out Aggravates Doxorubicin-Induced Cardiac Injury and Dysfunction by Aggravating the Inflammatory Response, Oxidative Stress, Apoptosis and Autophagy in Mice , 2018, EBioMedicine.

[10]  A. Angelini,et al.  Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth , 2018, Circulation.

[11]  Jianfang Liu,et al.  Inhibition of TRPA1 Attenuates Doxorubicin-Induced Acute Cardiotoxicity by Suppressing Oxidative Stress, the Inflammatory Response, and Endoplasmic Reticulum Stress , 2018, Oxidative medicine and cellular longevity.

[12]  N. Hadi,et al.  Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis , 2018, BMC Pharmacology and Toxicology.

[13]  Jun Ren,et al.  Rutin attenuates doxorubicin-induced cardiotoxicity via regulating autophagy and apoptosis. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[14]  M. Neurath,et al.  Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells , 2017, Nature Medicine.

[15]  J. Wu,et al.  Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity , 2016, Cell Death and Disease.

[16]  F. Giallauria,et al.  Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. , 2016, International journal of cardiology.

[17]  S. Raychaudhuri,et al.  IL-9, a local growth factor for synovial T cells in inflammatory arthritis. , 2016, Cytokine.

[18]  M. Ciccarelli,et al.  Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. , 2016, Toxicology and applied pharmacology.

[19]  S. Wen,et al.  IL-9 aggravates the development of atherosclerosis in ApoE-/- mice. , 2015, Cardiovascular research.

[20]  Kenji Suzuki,et al.  Myocardial 14-3-3η protein protects against mitochondria mediated apoptosis. , 2015, Cellular signalling.

[21]  M. Neurath,et al.  IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis , 2015, Tissue barriers.

[22]  Hulun Li,et al.  Neutralization of interleukin‐9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses , 2014, Immunology.

[23]  P. Oliveira,et al.  Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy , 2014, Medicinal research reviews.

[24]  Ying Huang,et al.  Circulating Th22 and Th9 Levels in Patients with Acute Coronary Syndrome , 2013, Mediators of inflammation.

[25]  D. Chung,et al.  IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner , 2012, Mucosal Immunology.

[26]  H. Crijns,et al.  Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. , 2012, Journal of molecular and cellular cardiology.

[27]  B. Nourbakhsh,et al.  IL‐9 is important for T‐cell activation and differentiation in autoimmune inflammation of the central nervous system , 2011, European journal of immunology.

[28]  L. Liaudet,et al.  Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. , 2007, Journal of the American College of Cardiology.

[29]  M. Okabe,et al.  Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Hong-sheng Zhang,et al.  Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[31]  L-L Pang,et al.  IL-9 exacerbates the development of chronic obstructive pulmonary disease through oxidative stress. , 2018, European review for medical and pharmacological sciences.

[32]  E. Sanchez,et al.  IL-9: Function, Sources, and Detection. , 2017, Methods in molecular biology.

[33]  S. Khoury,et al.  Th9 cells in the pathogenesis of EAE and multiple sclerosis , 2016, Seminars in Immunopathology.